BMJ · 1994 · 158 citations · 4 references
MedicineEndocrinologyPharmacotherapyBone MetabolismContraceptionReproductive EndocrinologyBone EndocrinologyBone HealthHormonal ContraceptionMenopause ManagementMenopause PharmacotherapyOsteoporosisBone Density ComparisonBone Loss From Hormone TherapyDrug Effects On Bone DensityDrug-induced Bone LossEstrogen MetabolismEstrogen SecretionOsteoporosis In WomenPostmenopausal Osteoporosis Treatment
In order to determine whether the loss in bone density seen in users of depot medroxyprogesterone acetate is reversible, a comparative study was undertaken in three groups of women. Group 1 consisted of 14 women who had used the contraceptive for at least 3 years and then discontinued use. Group 2 was 22 longterm users, and Group 3 contained 18 women who had never used the drug and served as controls. Estrogen production resumed in all of the Group 1 women after discontinuation. Two bone density measurements were taken twice in each woman. At first measurement, lumbar spine density was an average of 9% lower in Groups 1 and 2 than in controls. At the second measurement, however, lumbar spine density had significantly increased in Group 1 while it remained the same for the other groups. No significant changes in femoral neck density were observed. Additional measurements in 8 women from Group 1 taken 2 years after discontinuation revealed a further significant increase in lumbar spine bone density. Thus, it was concluded that bone density loss is reversible, even in cases where women experience a significant weight loss after discontinuation.
4
Scoliosis and Fractures in Young Ballet Dancers
Michelle P. Warren, J. Brooks Gunn, Linda Hamilton et al. · New England Journal of Medicine · 1986 · 479 citations
Bone density in women receiving depot medroxyprogesterone acetate for contraception.
Tim Cundy, M C Evans, Helen Roberts et al. · BMJ · 1991 · 254 citations · Full text
Medicine, Endocrinology, Gynecology +17